Rational development of targeted cancer therapies using biomarkers
As the complex network of signalling pathways involved in regulating tumor cell growth and survival is unraveled, tractable targets for therapeutic drug development have been identified. Questions regarding the best approach towards developing these targeted therapies remain [eg, what is the best strategy for (i) selecting doses, (ii) identifying target patient populations for clinical trials, and (iii) designing combination therapies based on scientific rationale]. Since these agents exert biological and clinical effects that are generally distinct from traditional cytotoxic agents, a different paradigm for their development has been suggested. Here we will discuss how incorporation of biomaker analysis in early-phase clinical trials can provide valuable information to guide further development of targeted therapies.
Bacus, S; Yarden, Y; Xia, W; Spector, NL
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)